1. Home
  2. MGRM vs SKYE Comparison

MGRM vs SKYE Comparison

Compare MGRM & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGRM
  • SKYE
  • Stock Information
  • Founded
  • MGRM 2016
  • SKYE 2012
  • Country
  • MGRM United States
  • SKYE United States
  • Employees
  • MGRM N/A
  • SKYE N/A
  • Industry
  • MGRM Medical/Dental Instruments
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • MGRM Health Care
  • SKYE Health Care
  • Exchange
  • MGRM Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • MGRM 89.6M
  • SKYE 80.7M
  • IPO Year
  • MGRM N/A
  • SKYE N/A
  • Fundamental
  • Price
  • MGRM $2.78
  • SKYE $2.98
  • Analyst Decision
  • MGRM Strong Buy
  • SKYE Buy
  • Analyst Count
  • MGRM 1
  • SKYE 6
  • Target Price
  • MGRM $4.00
  • SKYE $18.67
  • AVG Volume (30 Days)
  • MGRM 42.8K
  • SKYE 174.6K
  • Earning Date
  • MGRM 03-14-2025
  • SKYE 02-13-2025
  • Dividend Yield
  • MGRM N/A
  • SKYE N/A
  • EPS Growth
  • MGRM N/A
  • SKYE N/A
  • EPS
  • MGRM N/A
  • SKYE N/A
  • Revenue
  • MGRM $364,999.00
  • SKYE N/A
  • Revenue This Year
  • MGRM N/A
  • SKYE N/A
  • Revenue Next Year
  • MGRM N/A
  • SKYE N/A
  • P/E Ratio
  • MGRM N/A
  • SKYE N/A
  • Revenue Growth
  • MGRM N/A
  • SKYE N/A
  • 52 Week Low
  • MGRM $1.53
  • SKYE $2.31
  • 52 Week High
  • MGRM $4.90
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • MGRM 56.50
  • SKYE 49.42
  • Support Level
  • MGRM $2.62
  • SKYE $2.70
  • Resistance Level
  • MGRM $2.87
  • SKYE $4.25
  • Average True Range (ATR)
  • MGRM 0.14
  • SKYE 0.44
  • MACD
  • MGRM 0.00
  • SKYE 0.05
  • Stochastic Oscillator
  • MGRM 73.09
  • SKYE 32.80

About MGRM Monogram Orthopaedics Inc.

Monogram Technologies Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: